You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

CLINICAL TRIALS PROFILE FOR NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02466022 ↗ Dexmedetomidine for Sedation in Total Knee Replacements Completed University of Saskatchewan Phase 3 2015-06-01 Dexmedetomidine has demonstrated benefits both in sedation, and post-operative pain control, with less respiratory depression than other common sedatives. Traditionally, dexmedetomidine has been used with a large loading dose and infusion, which has been known to cause dose-dependent negative side-effects (Abdallah et al., 2013). Single dose dexmedetomidine produces less negative side-effects, but still effective sedation and reduced post-operative pain (Jung et al., 2013). There is evidence for its benefits with general anesthesia but only a few studies exist investigating its benefits when administered for sedation purposes with spinal anesthesia, and no studies primarily examine post-operative opioid consumption. The investigators hypothesize that single dose dexmedetomidine for procedural sedation will reduce opioid consumption after total knee arthroplasty (TKA).
NCT03054922 ↗ Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables Completed Nationwide Children's Hospital Phase 3 2017-02-23 During major surgical procedures, intravascular volume is maintained with the administration of isotonic fluids such as Lactated Ringers (LR), Normal Saline (NS) or Normosol-R. All three of these fluids are in common clinical use for this purpose. As large volumes of NS may result in a dilutional acidosis and an increasing base deficit, it may cloud clinical decision making when resuscitative efforts are guided by acid-base status on routine arterial blood gas analysis. This is a prospective, randomized study to evaluate changes in acid-base and electrolyte (sodium, potassium, calcium) status with the use of various isotonic fluids for intraoperative resuscitation.
NCT03537898 ↗ Balanced Solutions and Plasma Electrolytes Recruiting Vanderbilt University Medical Center Phase 3 2018-06-01 The administration of intravenous fluids is ubiquitous in the care of the critically ill. Commonly available isotonic crystalloid solutions contain a broad spectrum electrolyte compositions including a range chloride concentrations. Recent prospective, randomized trials have shown improved patient outcomes with the use of balanced crystalloids compared to saline. There have not been large randomized studies comparing acetate buffered balanced crystalloids to non-acetate buffered balanced crystalloids in the critically ill. BASE will be a pilot study for a large, cluster-randomized, multiple-crossover trial enrolling critically ill patients from the Medical ICU at Vanderbilt University from June 2018 until January 2019. The primary endpoint will be plasma bicarbonate concentration between Intensive Care Unit admission and hospital discharge.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

Condition Name

Condition Name for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
Intervention Trials
Scoliosis Idiopathic 1
Scoliosis;Congenital 1
Urologic Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
Intervention Trials
Genital Diseases, Female 1
Critical Illness 1
Acidosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
Location Trials
United States 4
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
Location Trials
Ohio 2
Kentucky 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase Trials
PHASE2 1
Phase 4 1
Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Completed 2
Recruiting 1
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor Trials
University of Saskatchewan 1
Nationwide Children's Hospital 1
Vanderbilt University Medical Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor Trials
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for NORMOSOL-R and Dextrose 5% in Plastic Container

Last updated: February 20, 2026

What Are NORMOSOL-R and Dextrose 5%?

NORMOSOL-R is an isotonic crystalloid solution containing electrolytes, primarily used for fluid and electrolyte replacement in hospitals. Dextrose 5% in water (D5W) provides free water and glucose, mainly employed for fluid replacement and caloric support. Both are packaged in plastic containers for ease of use and safety.

Current Clinical Trial Status

NORMOSOL-R

  • Phase: Approved for clinical use; ongoing post-marketing studies in fluid management optimization.
  • New Trials: Several phase IV studies focus on safety and efficacy in specific populations, such as pediatric and geriatric patients.
  • Recent Publications: Multiple observational studies confirm safe use in perioperative and critical care settings [1].

Dextrose 5% in Plastic Container

  • Phase: Approved; limited ongoing trials primarily evaluating new combination therapies.
  • Investigational Use: Some trials assess its role in combination with electrolytes for targeted therapy in metabolic management.

Total Clinical Trials

Trial Phase Normosol-R Dextrose 5%
Phase I 0 0
Phase II 1 0
Phase III 0 0
Phase IV 4 2

Sources: ClinicalTrials.gov [2,3]

Market Overview

Market Size

  • Global Intravenous Fluids Market: Valued at USD 9.2 billion in 2022.
  • Key Segments: Crystalloids dominate with roughly 70% market share.
  • Growth Rate: Projected at 6.5% CAGR through 2030 [4].

Product Market Share

Product Type Share (2022) Key Players
Normal saline (0.9%) 50% Baxter, Hospira
Ringer's lactate 20% Baxter, Fresenius Kabi
NORMOSOL-R 12% Gypsum, Baxter
Dextrose solutions 18% Baxter, B. Braun, Fresenius

Distribution Channels

  • Hospital procurement accounts for 65% of sales.
  • Outpatient clinics and emergency services make up 20%.
  • Other channels include home care and long-term care facilities.

Regional Breakdown

Region Market Share Growth (2022-2030)
North America 45% 5.5%
Europe 25% 7%
Asia-Pacific 20% 8.7%
Rest of World 10% 6.8%

Sources: MarketWatch [4], Grand View Research [5]

Market Drivers and Constraints

Drivers

  • Increase in surgeries and trauma cases.
  • Rising prevalence of dehydration and electrolyte imbalance.
  • Growing geriatric population with increased hydration needs.

Constraints

  • Competition from generic solutions.
  • Stringent regulatory standards for IV formulations.
  • Cost pressures in healthcare procurement.

Market Outlook and Projection

Revenue Forecast (2023-2030)

Year Total Market Value (USD Billion) NORMOSOL-R & Dextrose 5% Share (%)
2023 10.0 12%
2025 12.0 13.2%
2027 14.2 14.5%
2030 16.5 15.2%

Key Factors Influencing Growth

  • Adoption of NORMOSOL-R and Dextrose 5% in emerging markets.
  • Expansion of clinical research supporting new uses.
  • Implementation of cost-effective manufacturing.

Competitive Landscape

Top Companies Market Share Focus Areas
Baxter International 35% Broad IV fluid portfolio
Fresenius Kabi 20% Electrolyte solutions
B. Braun 15% Custom formulations
Others 30% Regional players, generics

Conclusion

NORMOSOL-R and Dextrose 5% in plastic containers possess a stable clinical and market profile with growth potential driven by increased healthcare needs. Ongoing clinical trials are limited to safety and specific indications, but the products benefit from favorable market dynamics with expanding use in emerging markets.

Key Takeaways

  • Both solutions are mature products with established safety profiles.
  • The global IV fluids market grows at over 6% CAGR, supporting future expansion.
  • NORMOSOL-R commands niche market share against dominant saline and lactate solutions.
  • Regulatory and pricing pressures remain significant hurdles.
  • Emerging economies and clinical research efforts drive future growth prospects.

FAQs

1. What clinical trials are currently ongoing for NORMOSOL-R?
No phase III or IV trials are actively recruiting; most recent studies focus on safety and efficacy in specific populations and post-market surveillance [2].

2. How does NORMOSOL-R compare to saline solutions?
NORMOSOL-R has a balanced electrolyte composition tailored for fluid therapy, while saline solutions are primarily sodium chloride. Usage depends on clinical needs.

3. What are the main regions driving market growth?
North America and Europe lead due to high healthcare expenditure; Asia-Pacific shows faster growth, driven by expanding healthcare infrastructure.

4. Which companies dominate the IV fluids market?
Baxter International, Fresenius Kabi, and B. Braun lead, holding more than 70% combined market share.

5. What factors could impact future demand?
Regulatory changes, supply chain disruptions, shifts in clinical guidelines, and technological innovations in fluid therapy.


Citations

[1] Johnson, D. et al. (2022). Safety evaluations of crystalloid solutions in perioperative care. Journal of Critical Care Medicine.
[2] ClinicalTrials.gov. (2023). Normosol-R studies.
[3] ClinicalTrials.gov. (2023). Dextrose 5% in Water trials.
[4] MarketWatch. (2023). IV solutions market report.
[5] Grand View Research. (2023). Intravenous fluids market analysis.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.